Sleep Apnea Pipeline Summary

DelveInsight’s, “Sleep Apnea - Pipeline Insight, 2026” report provides comprehensive insights about 22+ companies and 24+ pipeline drugs in Sleep Apnea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Sleep Apnea: Understanding

Sleep Apnea: Overview

Sleep Apnea syndrome (SAS) is a sleep-related breathing disorder characterized by recurrent episodes of apnea (complete cessation of airflow) and hypopnea (partial reduction in airflow) during sleep, leading to fragmented sleep, intermittent hypoxemia, and excessive daytime sleepiness. The syndrome encompasses obstructive, central, and mixed Sleep Apnea, with obstructive Sleep Apnea (OSA) being the most common form. In OSA, repetitive collapse of the upper airway during sleep causes snoring, breathing interruptions, and frequent arousals, which can contribute to significant cardiovascular, metabolic, and neurocognitive complications if left untreated.

The primary cause of obstructive Sleep Apnea is recurrent upper airway collapse during sleep due to anatomical and neuromuscular factors that reduce airway patency. Major risk factors include obesity, increasing age, male sex, craniofacial abnormalities such as retrognathia or maxillomandibular deficiency, enlarged upper airway soft tissues, smoking, and a family history of OSA. These factors narrow the upper airway or reduce its stability, making it more susceptible to collapse during sleep. Central Sleep Apnea, in contrast, results from impaired central respiratory drive rather than airway obstruction.

The pathophysiology of obstructive Sleep Apnea is driven by reduced tonic activity of the upper airway dilator muscles during sleep, causing dynamic narrowing or complete collapse of the airway. This leads to repeated episodes of apnea or hypopnea, resulting in intermittent hypoxia, hypercapnia, and recurrent sleep arousals that restore airway patency. These repetitive events increase sympathetic nervous system activity, oxidative stress, systemic inflammation, and fluctuations in intrathoracic pressure, ultimately contributing to hypertension, cardiovascular disease, metabolic dysfunction, impaired cognitive performance, and reduced quality of life. Airway obstruction may occur at multiple anatomical levels, including the nasal cavity, nasopharynx, oropharynx, tongue base, and larynx.

Diagnosis of Sleep Apnea syndrome begins with a comprehensive clinical history and physical examination focusing on symptoms such as excessive daytime sleepiness, loud snoring, witnessed apneas, nocturnal choking or gasping, morning headaches, and poor sleep quality. Examination includes assessment of the upper airway to identify anatomical causes of obstruction.

Treatment of Sleep Apnea syndrome aims to maintain airway patency, improve sleep quality, and reduce long-term complications. Lifestyle modifications, including weight reduction, regular exercise, improved sleep hygiene, positional therapy, and avoidance of alcohol or sedative medications, are recommended for all patients. Continuous positive airway pressure (CPAP) therapy is the first-line treatment for most patients with obstructive Sleep Apnea and remains the standard of care, effectively reducing respiratory events, daytime sleepiness, and cardiovascular risk.

"Sleep Apnea- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sleep Apnea pipeline landscape is provided which includes the disease overview and Sleep Apnea treatment guidelines. The assessment part of the report embraces, in depth Sleep Apnea commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sleep Apnea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Sleep Apnea R&D. The therapies under development are focused on novel approaches to treat/improve Sleep Apnea.

Sleep Apnea Emerging Drugs Chapters

This segment of the Sleep Apnea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Sleep Apnea Emerging Drugs

• Zenagamtide: Novo Nordisk A/S

Zenagamtide (NNC0487-0111) is an investigational peptide therapy being which approach is based on reducing excess body weight, which is a major contributor to upper airway obstruction during sleep and disease severity. The therapy is intended for adults with overweight or obesity, where excess body weight is a key contributor to OSA severity. The company is evaluating zenagamtide for its potential to achieve clinically meaningful weight reduction and to improve Sleep Apnea by addressing the underlying obesity associated with upper airway obstruction during sleep. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Sleep Apnea.

• IBI362: Innovent Biologics (Suzhou) Co. Ltd.

IBI362 is an investigational dual glucagon-like peptide-1 (GLP-1) receptor and glucagon receptor (GLP-1R/GCGR) agonist developed by Innovent Biologics (Suzhou) Co. Ltd. for the treatment of moderate-to-severe obstructive Sleep Apnea (OSA) in adults with obesity. Administered as a once-weekly subcutaneous injection, IBI362 is designed to promote substantial weight loss through appetite suppression, delayed gastric emptying, and increased energy expenditure mediated by dual GLP-1 and glucagon receptor activation. By reducing obesity which is a major contributor to upper airway obstruction it is expected to decrease the severity of OSA and improve sleep-related breathing disturbances. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Sleep Apnea.

• IHL-42X: Incannex Healthcare

IHL-42X is an investigational oral fixed-dose combination therapy of dronabinol and acetazolamide administered once daily, IHL-42X is designed to target two complementary mechanisms underlying OSA: dronabinol, a cannabinoid receptor agonist, enhances upper airway neuromuscular tone and respiratory drive, while acetazolamide, a carbonic anhydrase inhibitor, improves ventilatory stability by reducing loop gain and mitigating intermittent hypoxia and hypercapnia. This dual mechanism aims to reduce upper airway collapse and the frequency of apnea–hypopnea events during sleep. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Sleep Apnea.

• MOS118: Mosanna Therapeutics

MOS118 is an investigational intranasal small-molecule therapy developed by Mosanna Therapeutics for the treatment of obstructive Sleep Apnea (OSA). Administered as a bedtime nasal spray, MOS118 is designed to restore the body's natural upper airway reflexes by temporarily modulating the neuromuscular control of the throat and upper airway muscles, thereby reducing airway collapse during sleep and maintaining airway patency. Unlike mechanical therapies such as CPAP, MOS118 targets the underlying neuromuscular dysfunction associated with OSA through a non-invasive pharmacological approach. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Sleep Apnea.

Further product details are provided in the report……..

Sleep Apnea: Therapeutic Assessment

This segment of the report provides insights about the different Sleep Apnea drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Sleep Apnea

There are approx. 22+ key companies which are developing the therapies Sleep Apnea. The companies which have their Sleep Apnea drug candidates in the most advanced stage, i.e. Phase III include, Novo Nordisk A/S and others.

• Phases

DelveInsight’s report covers around 24+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Sleep Apnea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Sleep Apnea: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sleep Apnea therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sleep Apnea drugs.

Sleep Apnea Report Insights

• Sleep Apnea Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Sleep Apnea Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Sleep Apnea drugs?
• How many Sleep Apnea drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Sleep Apnea?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Sleep Apnea therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Sleep Apnea and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Novo Nordisk A/S
• Innovent Biologics (Suzhou) Co. Ltd.
• Incannex Healthcare
• Mosanna Therapeutics
• Apnimed
• Desitin Arzneimittel GmbH
• Shionogi Apnimed Sleep Science
• KYORIN Pharmaceutical Co., Ltd
• Amgen
• Hangzhou Sciwind Biosciences Co., Ltd.

Key Products

• Zenagamtide
• IBI362
• IHL-42X
• MOS118
• AD109
• Sulthiame
• SASS-001
• KRP-S124
• Maridebart cafraglutide
• XW003